Voluntary announcement - UTD2 of biostar achieves first patient dosing in phase iii clinical study for HER2-negative advanced breast cancer
Filed with HKEX · Stock code 2563 ·
6ix is reading this filing.
View original source (HKEXnews)Beijing Biostar Pharmaceuticals Co., Ltd. on 6ix
Earlier from Beijing Biostar Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Interim Report 2026
- Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
- The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
- Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
Follow Beijing Biostar Pharmaceuticals into a list and get an email when it puts out news.
Follow Beijing Biostar Pharmaceuticals